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INTRODUCTION 
Infantile myofibromatosis (IM), predominantly observed in infants and young children, features 
variable prognosis, as evidenced by some tumors spontaneously regressing, others successfully 
surgically managed, and those multi-focal or with visceral involvement requiring systemic therapy1-3.  
For patients with unresectable, persistent, and disseminated IM, comprehensive genomic profiling 
(CGP) may identify targetable genomic alterations. In this case of a child with a single focus 
unresectable IM, CGP identified a novel MYH10-RET fusion, suggesting possible utility of RET 
targeted therapies. 
 
RESULTS 
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The index patient is a newborn female with a large mass in the left sacrum and inability to move 
lower extremities. Magnetic resonance imaging (MRI) revealed a single large multi-lobulated 
retroperitoneal mass encasing the lumbosacral spine, with a portion of the mass within the 
lumbosacral spinal canal and multiple neural foramina bilaterally. This mass encased multiple vessels 
and narrowed the iliac veins bilaterally and the inferior vena cava. Surgical resection was deemed 
unfeasible. 
Biopsy revealed a moderately cellular lesion composed of spindle cells with a fascicular architecture 
and some areas displaying prominent hemangiopericytomatous vascular pattern with adipose tissue 
infiltration. Patchy extramedullary hematopoiesis and focal intervascular extension by the tumor 
were noted.  CD34, HHF35, desmin and myogenin were negative, whereas smooth muscle actin was 
focally and weakly positive.  Based on these features and FISH negativity for the t(12;15)(p13;q25) 
ETV6-NTRK3 translocation, the diagnosis was a low-grade spindle cell tumor consistent with IM. 
 
Initial treatment with vincristine, actinomycin-D, and cyclophosphamide was poorly tolerated, 
leading to necrotizing enterocolitis, liver dysfunction and veno-occlusive disease.  Subsequent 
weekly vinblastine and methotrexate (VBL/MTZ) were well-tolerated - after 26 weeks, tumor shrunk 
by ~40%, and neurologic function of extremities and urinary continence improved.  Currently at 42 
weeks on VBL/MTZ, she is continuing to respond. 
 
CGP of the tumor revealed a single alteration, a MYH10-RET fusion (Figure 1). 
 
DISCUSSION 
  
 
This article is protected by copyright. All rights reserved. 
4 
 
This is the first report describing a RET fusion in IM.  In lung and thyroid carcinomas, RET fusions are 
established oncogenic drivers, sensitive to RET inhibitors4,5. MYH10-RET, although novel, has the 
same domain structure as the well-characterized KIF5B-RET, indicating that this fusion is an 
oncogenic driver. 
This finding also suggests broadening of diagnostic possibilities.  Previously, familial IM has been 
associated with mutations of PDGFRB6,7.  Kinase fusions, particularly involving ALK, but also ROS1, 
PDGFRB, and RET, are observed in a related entity, inflammatory myofibroblastic tumor (IMT). The 
differential diagnosis for this lesion does include IMT, and morphologic and immunohistochemical 
features of both entities do overlap.  Since RET alterations have never previously been observed in 
IM but have been observed in IMT, it is possible that this lesion might be characterized as an IMT 
under other circumstances8. 
Importantly, IMTs harboring various kinase fusions, including ALK and ROS1, were sensitive to small 
molecule kinase inhibitors9,10. 
For this child, identification of the MYH10-RET fusion indicates possible benefit from RET inhibitors. 
Further CGP myofibromatosis and IMT should reveal whether RET fusions are a recurrent feature of 
aggressive myofibromatosis or whether the index case is genomically unique and may be better 
characterized as an IMT. 
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Legends 
Figure 1. Identification of a MYH10-RET fusion in the soft tissue myofibromatosis. A rearrangement 
between the MYH10 and RET loci resulted in a MYH10-RET fusion protein that is predicted to include 
the MYH10 myosin motor, IQ domain and a portion of the coiled-coil domain, as well as the entire 
kinase domain of RET. 
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Supplemental Figure S1. Identification of a MYH10-RET fusion in the soft tissue myofibromatosis. 
DNA sequencing (top panel) identified a rearrangement between the RET locus on 10q11 (blue bars) 
and the MYH10 locus on 17p13.1 (pink bars). Break points are in intron 33 of MYH10 and intron 11 
of RET. RNA sequencing (bottom panel) identified an in-frame fusion joining exons 1-33 (residues 1-
1598, NM_005964) of MYH10 with exons 12-19 (residues 713-1072, NM_020630) of RET. 
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